Omarigliptin

Omarigliptin
Clinical data
Routes of
administration		 Oral
ATC code
  • None
Legal status
Legal status
  • Developing
Identifiers
Synonyms MK-3102
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C17H20F2N4O3S
Molar mass 398.427506 g/mol
3D model (JSmol)

Omarigliptin (MK-3102) is a potent, long-acting oral antidiabetic drug of the DPP-4 inhibitor class used for once-weekly treatment of type 2 diabetes and currently under development by Merck & Co.[1] It inhibits DPP-4 to increase incretin levels (GLP-1 and GIP),[2][3][4] which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying and decreases blood glucose levels.

History

Marizev (omarigliptin) 25 mg and 12.5 mg tablets were approved by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) on 28th Sept 2015. Japan was the first country to have approved omarigliptin.[5] However Merck has announced that the company will not submit marketing application in the US and Europe. [6]

References

  1. ↑ "Pharmacokinetics of Omarigliptin (Mk-3102), A Once-Weekly Dipeptidyl Peptidase-IV (DPP-4) Inhibitor, in Patients With Renal Impairment" (PDF). Merck & Co., Inc. Retrieved 20 September 2015.
  2. ↑ McIntosh, C; Demuth, H; Pospisilik, J; Pederson, R (2005). "Dipeptidyl peptidase IV inhibitors: How do they work as new antidiabetic agents?". Regulatory Peptides. 128 (2): 159–65. PMID 15780435. doi:10.1016/j.regpep.2004.06.001.
  3. ↑ Behme, Margaret T; Dupré, John; McDonald, Thomas J (2003). "Glucagon-like peptide 1 improved glycemic control in type 1 diabetes". BMC Endocrine Disorders. 3 (1): 3. PMC 154101 Freely accessible. PMID 12697069. doi:10.1186/1472-6823-3-3.
  4. ↑ Dupre, J.; Behme, M. T.; Hramiak, I. M.; McFarlane, P.; Williamson, M. P.; Zabel, P.; McDonald, T. J. (1995). "Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM". Diabetes. 44 (6): 626–30. PMID 7789625. doi:10.2337/diabetes.44.6.626.
  5. ↑ "Merck MARIZEV Once-Weekly DPP-4 Inhibitor For Type2 Diabetes Approved In Japan". NASDAQ. 28 September 2015. Retrieved 29 September 2015.
  6. ↑ http://www.mercknewsroom.com/news/company-statements/merck-provides-update-filing-plans-omarigliptin-investigational-dpp-4-inhibi

See also

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.